Anle138b

  Cat. No.:  DC10168   Featured
Chemical Structure
882697-00-9
For research use only. We do not sell to patients.
We match the best price and quality on market.
Email:order@dcchemicals.com  sales@dcchemicals.com
Tel:+86-021-58447131
We are official vendor of:
  • 20
  • 19
  • 18
  • 17
  • 16
  • 15
  • 14
  • 12
  • 11
  • 10
  • 9
  • 8
  • 13
  • 6
  • 5
  • 4
  • 3
  • 2
  • 1
More than 5000 active chemicals with high quality for research!
Field of application
Anle138b is a novel oligomer modulator.
Cas No.: 882697-00-9
Chemical Name: Anle138b
Synonyms: Anle138b;Anle-138b;3-(1,3-Benzodioxol-5-yl)-5-(3-bromophenyl)-1H-pyrazole;5-(1,3-Benzodioxol-5-yl)-3-(3-bromophenyl)-1H-pyrazole;Anle 138b;CID 44608289;BCP32558;Anle138b, >=98% (HPLC);NSC805132;s6782;DB13927;3-(1,3-Benzodioxole-5-yl)-5-(3-bromophenyl)-1H-pyrazole;3-(Benzo[d][1,3]dioxol-5-yl)-5-(3-bromophenyl)-1H-pyrazole
SMILES: BrC1=C([H])C([H])=C([H])C(=C1[H])C1C([H])=C(C2C([H])=C([H])C3=C(C=2[H])OC([H])([H])O3)N([H])N=1
Formula: C16H11BrN2O2
M.Wt: 343.1747
Sotrage: 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO
Description: Anle138b is a novel oligomer modulator.
In Vivo: Anle138b has no detectable toxicity at therapeutic doses and an excellent oral bioavailability and blood–brain-barrier penetration. In mouse models of prion disease and in three different PD mouse models, anle138b strongly inhibits oligomer accumulation, neuronal degeneration, and disease progression[1]. Di-phenyl-pyrazole anle138b binds to aggregated tau and inhibits tau aggregation. Anle138b treatment effectively ameliorates disease symptoms, increases survival time and improves cognition of tau transgenic PS19 mice[2].
In Vitro: Oligomeric aggregates are presumed to be the key neurotoxic agent. Anle138b blocksthe formation of pathological aggregates of prion protein and of α-synuclein, which is deposited in Parkinson’s disease and other synucleinopathies such as dementia with Lewy bodies and multiple system atrophy. Anle138b strongly inhibits all prion strains tested including BSE-derived and human prions. Anle138b shows structure-dependent binding to pathological aggregates and strongly inhibits formation of pathological oligomers both for prion protein and α-synuclein[1].
MSDS
COA
LOT NO. DOWNLOAD
2018-0101
2018-0101
Cat. No. Product name Field of application
DC10168 Anle138b Anle138b is a novel oligomer modulator.
X